04/23/2026
There is more than one way to target the PD-1/PD-L1 immune checkpoint pathway in advanced cutaneous squamous cell carcinoma (cSCC), and the differences matter clinically.
In just 10 minutes, Vishal Patel, MD, and David M. Miller, MD, PhD, walk through how to distinguish these agents by mechanism, weigh their efficacy and safety profiles, and factor in patient-specific considerations when selecting a checkpoint inhibitor for cSCC.
Earn up to 0.25 πππ πππ ππ’π΅π¦π¨π°π³πΊ 1 ππ³π¦π₯πͺπ΅π΄β’
This activity is supported by an educational grant from Sun Pharmaceutical Industries Ltd.
Start the activity: https://bit.ly/4cEhHPU